-

Company Profile for ReAlta Life Sciences, Inc.

--(BUSINESS WIRE)--ReAlta Life Sciences, Inc. is a clinical stage biotech company dedicated to harnessing the power of the immune system through its PIC1 technology platform, comprised of a family of over 160 engineered peptides, to address life-threatening medical needs. To support its vision, ReAlta has developed a novel class of therapeutics with a dual targeting approach designed to rebalance complement and inflammatory processes in the body.  The company’s pipeline is led by RLS-0071, which has been granted Orphan Drug Designation by the U.S. Food and Drug Administration and European Medicines Agency for the treatment of hypoxic-ischemic encephalopathy (HIE) in neonates, and is also being developed as a treatment for acute lung injury secondary to COVID-19. The company launched in 2018, and is located in Norfolk, Virginia. For more information, please visit www.realtalifesciences.com.

Company:

ReAlta Life Sciences, Inc.

 

 

Headquarters Address:

5665 Lowery Road

 

Norfolk, VA 23502

 

 

Main Telephone:

7579010460

 

 

Website:

www.realtalifesciences.com

 

 

Type of Organization:

Private

 

 

Industry:

Pharmaceutical

 

 

Key Executives:

CEO: Ulrich Thienel

 

 

Public Relations

 

Contact:

Alicia Davis

Phone:

(910) 620-3302

Email:

alicia@thrustsc.com

 

Industry:

ReAlta Life Sciences, Inc.

Details
Headquarters: Norfolk, Virginia
CEO: David Marek
Employees: 20-50
Organization: PRI
Release Versions
English
More News From ReAlta Life Sciences, Inc.

ReAlta Life Sciences Announces First Patient Dosed in Phase 2 Study Evaluating RLS-0071 for the Treatment of Steroid-Refractory Acute Graft-versus-Host Disease

NORFOLK, Va.--(BUSINESS WIRE)--ReAlta Life Sciences, Inc. ("ReAlta" or the “Company”), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the inflammatory response to address rare and acute inflammatory diseases, today announced that the first patient has been dosed in its Phase 2 study of RLS-0071, the Company’s lead therapeutic candidate, for the treatment of hospitalized patients with moderate to very severe steroid-refractory acute graft-versus-host disease...

ReAlta Life Sciences Further Bolsters Experienced Executive Team with the Appointment of Peter Ho, Ph.D., as Head of Business Development and Corporate Strategy

NORFOLK, Va.--(BUSINESS WIRE)--ReAlta Life Sciences, Inc. ("ReAlta" or the “Company”), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the inflammatory response to address rare and acute inflammatory diseases, today announced that Peter Ho, Ph.D., has joined the Company as Head of Business Development and Corporate Strategy. “I am thrilled to have Peter join our executive team at this pivotal time as we advance our three Phase 2 programs in rare and acute inf...

ReAlta Life Sciences Invigorates Executive Team with Appointments of David Marek as Chief Executive Officer and Paolo Martini, Ph.D., as Chief Research and Development Officer

NORFOLK, Va.--(BUSINESS WIRE)--ReAlta Life Sciences, Inc. ("ReAlta" or the “Company”), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the inflammatory response to address rare and acute inflammatory diseases, today announced two distinguished biopharmaceutical veterans to lead the Company: David Marek appointed as Chief Executive Officer and Paolo Martini, Ph.D., appointed as Chief Research and Development Officer. “As ReAlta evolves into a late-stage develo...
Back to Newsroom
  1. There was an issue with the authorization server. Please contact support if the issue persists.